Karyopharm Therapeutics (KPTI) PT Raised to $20.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective increased by research analysts at JPMorgan Chase from $19.00 to $20.00 in a research note issued on Tuesday. The firm presently has an “overweight” rating on the stock. JPMorgan Chase’s target price points to a potential upside of 58.23% from the stock’s current price.

A number of other equities research analysts have also recently commented on KPTI. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, December 12th. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Tuesday, December 12th. BidaskClub raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. ValuEngine raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 8th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and issued a $22.00 price target on shares of Karyopharm Therapeutics in a report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $20.20.

NASDAQ:KPTI opened at $12.64 on Tuesday. The company has a market capitalization of $595.83, a P/E ratio of -4.50 and a beta of 3.61. Karyopharm Therapeutics has a 12 month low of $7.48 and a 12 month high of $18.00.



Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, March 15th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.14). The company had revenue of $1.53 million for the quarter, compared to the consensus estimate of $2.26 million. The company’s revenue for the quarter was up 3163.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.65) earnings per share. analysts expect that Karyopharm Therapeutics will post -2.83 earnings per share for the current fiscal year.

In related news, insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $12.50, for a total value of $125,000.00. Following the completion of the transaction, the insider now directly owns 723,510 shares in the company, valued at approximately $9,043,875. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Christopher Brett Primiano sold 2,500 shares of Karyopharm Therapeutics stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $16.03, for a total transaction of $40,075.00. Following the completion of the transaction, the executive vice president now owns 4,881 shares of the company’s stock, valued at $78,242.43. The disclosure for this sale can be found here. Insiders sold a total of 69,000 shares of company stock valued at $952,625 over the last quarter. 14.71% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in shares of Karyopharm Therapeutics by 753.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock valued at $3,342,000 after purchasing an additional 271,208 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Karyopharm Therapeutics by 6.4% during the 4th quarter. Franklin Resources Inc. now owns 3,337,569 shares of the company’s stock valued at $32,041,000 after purchasing an additional 200,310 shares in the last quarter. Iguana Healthcare Management LLC grew its position in shares of Karyopharm Therapeutics by 33.3% during the 3rd quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock valued at $4,392,000 after purchasing an additional 100,000 shares in the last quarter. Nationwide Fund Advisors grew its position in shares of Karyopharm Therapeutics by 396.0% during the 3rd quarter. Nationwide Fund Advisors now owns 105,664 shares of the company’s stock valued at $1,160,000 after purchasing an additional 84,362 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in shares of Karyopharm Therapeutics by 172.7% during the 4th quarter. Alliancebernstein L.P. now owns 118,430 shares of the company’s stock valued at $1,137,000 after purchasing an additional 75,000 shares in the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://dakotafinancialnews.com/2018/04/12/karyopharm-therapeutics-kpti-pt-raised-to-20-00.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply